MedTrace Logo

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

NCT03333187 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2025-03-30

No results posted yet for this study

Summary

The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.

Conditions

  • Bone Marrow Fibrosis

Interventions

PROCEDURE

Allogeneic stem cell transplantation

DRUG

Ruxolitinib continuous therapy

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Clinical Trial Center North (CTC North GmbH & Co. KG)

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Nicolaus Kröger, Prof. Dr. · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-21
Primary Completion
2024-10-07
Completion
2025-10-07

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03333187 on ClinicalTrials.gov